gonadotropin

(redirected from glycoprotein hormone)
Also found in: Dictionary, Thesaurus, Medical.
Related to glycoprotein hormone: TSH

gonadotropin

[gō‚nad·ə′trō·pən]
(biochemistry)
A substance that acts to stimulate the gonads.
References in periodicals archive ?
AKB-6548 is an orally bioavailable HIF-PH inhibitor designed to increase natural production of EPO, a glycoprotein hormone that controls red blood cell production, and causes a controlled rise in hemoglobin levels.
hCG is a glycoprotein hormone composed of 2 dissimilar subunits designated [alpha] and [beta].
based biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs for human infertility and animal superovulation as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.
The pregnancy marker human Chorionic gonadotropin (hCG) [3] (1, 2), a 37-kDa glycoprotein hormone synthesized by the trophoblast cells of placenta, is one of the most commonly measured markers both in clinical laboratories and in point-of-care (POC) settings.
Thus it is possible to design hCG assays that detect various forms of hCG equally and to standardize immunoassays for at least this glycoprotein hormone.
Erythropoietin, or its alternatives erythropoetin or erithropoyetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production.
The scheme centered on three drugs routinely administered to patients during dialysis: Venofer, an iron supplement; Zemplar, a vitamin D analog; and Epogen, a glycoprotein hormone also known as EPO.
Hyperglycosylated human chorionic gonadotropin (HhCG) is a glycoprotein hormone secreted during embryonic implantation and trophoblast invasion of the uterine wall and is an early marker of pregnancy (1).
Proceeds from the financing will be used to advance the clinical development of Protemix's lead product, PX811019, as a potential treatment for diabetic heart failure, as well as the continued preclinical development of PX811013, a novel form of the glycoprotein hormone adiponectin, and other earlier stage programs in the company's pipeline.